Ladenburg initiated coverage of Traws Pharma (TRAW) with a Buy rating and $6.50 price target The firm says the company offers an alternative to Cidara’s CD388.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW:
- Traws Pharma Completes Phase 2 Enrollment for COVID Candidate
- Traws Pharma completes enrollment in Phase 2 study of ratutrelvir
- Traws Pharma’s TRX-100 Phase 1 Completion: A Quiet but Key Milestone for Investors
- Traws Pharma advances flu and COVID-19 antiviral pipeline
- Traws Pharma files tivoxavir marboxil IND application with U.S. FDA